Merah Putih Vaccine Seeds Meet Industry Standards

Eijkman's Red and White vaccine research from recombinant proteins expressed in mammalian cells has succeeded in obtaining vaccine seeds that meet industry standards. In the next few months, it is hoped that the Red and White vaccine seeds will be processed for preclinical and clinical trials.

A senior researcher at the Center for Molecular Biology Research (PRBM) Eijkman National Research and Innovation Agency (BRIN) Tedjo Sasmono said that among a number of virus-forming devices (platforms), Eijkman researchers developed a red and white vaccine based on recombinant proteins. The protein is produced in yeast cells or mammalian cells. "The Red and White vaccine seeds developed by Eijkman are already at PT Bio Farma and meet industry standards. Initial characterization has been carried out with pretty good results. In a few months, it is hoped that preclinical and clinical trials can begin," he said at an online Covid-19 vaccine development research event. According to Tedjo, researchers must partner with the pharmaceutical industry because research institutions are not ready to produce vaccines or drugs on a large scale. Therefore, researchers must know the requirements for vaccine seeds for industry.

|•SOURCE•| Articles :KOMPAS | Image :PIKIRAN RAKYAT |

READ MORE

|• NATIONAL •|Guaranteed Cooking Oil Stock
|• INTERNATIONAL •|Property Giant is Still Question-mark
|• TECHNOLOGY •|Rooftop solar power plant investment
|• TIPS AND WISDOM •|Just do a good thing
|• SCIENCE •|INDONESIA Can Be Free from Imports of Fuel by 2030